Taiwan Industry Reports
Industry Type:   Title:  

 
Global Coronavirus (COVID-19) Pandemic and Impacts on Taiwan Biotechnology and Medicine Industry
2020-MayDoc　#32762Industry Report (condensed version)US$100
To spread the risks, local pharmaceutical companies hinge upon the procurement of active pharmaceutical ingredients from the sources of multiple suppliers, carry out the vertical integration of supply chains of the pharmaceutical industry, and develop niche drugs.
Coronavirus Disease (COVID-19) Outbreak – Impacts of Wuhan Epidemic on Taiwan Biotechnology Industry
2020-FebDoc　#32446Industry Report (condensed version)US$100
COVID-19 epidemic will have short term, weak positive impact on each segment of Taiwan’s biotechnology industry.
Food Biotechnology Industry
2019-DecDoc　#31936Industry Report (condensed version)US$100
Owing to a steady growth of the market for functional drinks and probiotic applications, the output value of the food biotechnology industry will increase marginally in 2020 from a year earlier, suggesting business conditions will slightly be favorable.
Raw Material Medicine Manufacturing
2019-AugDoc　#31280Industry Report (condensed version)US$100
The benefits of vertical integration are gradually becoming apparent, and firms within the industry continue to enter the emerging markets through niche products. Consequently, the industry is expected to witness a slight increase in sales in the third quarter of 2019.
Food Biotechnology Industry
2019-AprDoc　#30670Industry Report (condensed version)US$100
Both output and sales of the industry are expected to maintain a steady growth, while demand for functional beverages and dietary supplements will remain strong in China, prompting major industry participants to be active in expanding the production lines.
Food Biotechnology Industry
2018-JunDoc　#29121Industry Report (condensed version)US$75
Boosted by a sharp increase in demand for dietary Supplement in China, Taiwanese firms, Grape King Inc. and TCI Bio Corporation Limited Corporation Limited continue to develop plans to build factories and explore the China market.
Regenerative Medicine
2017-MarDoc　#27026Industry Report (condensed version)US$75
Although the industry is expected to see a slight growth in output value, ranging from 3 percent to 5 percent, the industry is still in its embryonic stage.
Food Biotechnology Industry
2016-DecDoc　#26450Industry Report (condensed version)US$75
China’s nutritional food improves and will contribute to a steady growth in the production value of Taiwan’s food biotechnology industry in 2017.
Regenerative Medicine Industry
2016-JunDoc　#25563Industry Report (condensed version)US$75
The industry’s output value is expected to rise marginally by 3 – 5 percent year-on-year in the first half of 2016.
Agricultural Biotechnology Industry
2016-JanDoc　#24872Industry Report (condensed version)US$75
In the first ten months of 2015, Taiwan’s exports of bottle orchid seedlings fell by 4.53 percent in value because of China’s ban on imports. However, other animal vaccines enjoyed a strong growth, and Taiwan’s effort to support the agricultural biotechnology industry lifted other animal vaccines industry.
 First  Previous  Next  Last  In  1  /  4  Page  (Find  38  records)
 





Copyright (c) 2018 All Rights Reserved by
Taiwan Institute of Economic Research
Taiwan Industry Economics Services
Address: 4Fl., 16-8, Tehui St., Taipei, Taiwan
TEL: 886-2-25865000 ext469; FAX: 886-2-25935543